Boundless Bio Q2 2026: $72.6M Cash, $37.2M Loss, Merger with Serapha Bio on Track
BOLD has more than doubled off its 52-week low of $0.961 on light trading volume (0.2× avg).
Summary
Boundless Bio burned $35.9M in H1 2026, leaving $72.6M in cash. The company has halted all R&D, cut 75% of staff, and is betting everything on a reverse merger with Serapha Bio. If the deal fails, liquidation is on the table.
Key Events · Earnings and Guidance · BOLD
-
Cash Burn Accelerates
Net cash used in operations was $35.9M in H1 2026, up from $26.4M a year ago, driven by a $37.2M net loss and a $10.0M lease termination payment. Cash and investments stand at $72.6M as of June 30, 2026.
-
Pipeline Abandoned, Workforce Slashed
The company ceased development of BBI-940 after poor clinical data and cut 75% of its workforce, incurring $2.8M in severance charges. All legacy oncology programs are now halted.
-
Merger with Serapha Bio Is Existential
The reverse merger with Serapha Bio, announced June 22, 2026, would give Boundless Bio shareholders just 3.69% of the combined company. A pre-closing dividend of $44–48M is planned. If the deal fails, the company may liquidate.
-
Facility Exit Costs Hit Earnings
Termination of the headquarters lease cost $10.0M in cash plus $0.5M security deposit forfeiture. The company also recognized $1.6M in asset impairment and $6.2M in accelerated lease amortization.
Analysis · BOLD · Life Sciences
Boundless Bio's Q2 2026 report reveals a rapidly deteriorating financial position with a net loss of $37.2 million and cash burn of $35.9 million in the first half, leaving $72.6 million in cash and investments. The company has abandoned its oncology pipeline after BBI-940 failed, terminated its headquarters lease at a cost of $10 million, and cut 75% of its workforce. The pending reverse merger with Serapha Bio is the only path forward — if it fails, the company warns it may liquidate. The report also details $2.8 million in severance charges, $1.6 million in asset impairments, and accelerated vesting of 5.9 million stock options, adding $2.0 million in stock-based compensation expense. The pre-closing dividend of $44–48 million will further deplete cash. This is a make-or-break moment for shareholders.
At the time of this filing, BOLD was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.8M. The 52-week trading range was $0.96 to $2.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.